- Home
- IOVA vs PRME Comparison
IOVA vs PRME Comparison
Compare IOVA & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IOVA | PRME |
|---|---|---|
| Founded | 2007 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 968.6M | 666.1M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | IOVA | PRME |
|---|---|---|
| Price | $2.54 | $3.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $10.45 | $6.42 |
| AVG Volume (30 Days) | ★ 12.0M | 3.8M |
| Earning Date | 11-06-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $250,425,000.00 | $5,977,000.00 |
| Revenue This Year | $60.71 | $111.80 |
| Revenue Next Year | $59.52 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 175.62 | ★ 647.13 |
| 52 Week Low | $1.64 | $1.11 |
| 52 Week High | $8.15 | $6.94 |
Technical Indicators
Market Signals| Indicator | IOVA | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 51.51 | 41.10 |
| Support Level | $2.69 | $3.29 |
| Resistance Level | $2.89 | $4.12 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 50.55 | 17.12 |
Price Performance
Historical ComparisonAbout IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About PRME Prime Medicine Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.